The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 20, 2016

Filed:

Oct. 04, 2012
Applicants:

Effimune, Nantes, FR;

Institut National DE LA Sante ET DE LA Recherche Medicale, Paris, FR;

Inventors:

Sophie Brouard, Suce sur Erdre, FR;

Le Hoa Mai, Orvault, FR;

Caroline Mary, Sainte-Pazanne, FR;

Nicolas Poirier, Treillieres, FR;

Jean-Paul Soulillou, Nantes, FR;

Bernard Vanhove, Reze, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/48 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/244 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 47/48215 (2013.01); C07K 16/2866 (2013.01); A61K 2039/505 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

The invention concerns antibodies directed against CD127, I.e. the alpha chain of the receptor for interleukin7 (IL-7), especially the receptor for human IL-7 expressed on human cells (designated human IL-7R alpha or IL-7Ra) or the TSLP receptor. The antibodies of the invention have cytotoxic activity against CD127 positive cells. The invention also relates to the use of these antibodies in order to deplete subpopulations of T lymphocytes as a result of cytotoxic action of the antibodies, through ADCC and optionally through CDC. Accordingly the invention concerns the use of the antibodies in the treatment of transplant rejection, autoimmune diseases, allergic diseases, lymphoma or cancer when these pathologies are associated with CD127 positive cells.


Find Patent Forward Citations

Loading…